Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant-Adjuvant Pembrolizumab in Advanced Basal Cell Carcinoma
NCT04323202Phase 1Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Aug 2020
- Primary completion
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in basal cell carcinoma (BCC), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Pathologic response as assessed by change in tumor volume (RECIST 1.1). Started Aug 2020; status: completed.
02
Drugs
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT04323202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04323202.